Search for content, post, videos

New results from Spago Nanomedical

Mats Hansen SpagoPix
Interim results from the second dose group in the company's ongoing clinical phase I study SPAGOPIX-01 show that SpagoPix (SN132D) is well tolerated and provides clear contrast enhancement in MRI images of solid tumors in the breast, as well as in the pancreas and liver. Based on the results, the
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.